Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA _1c without causing weight gain or increased hypoglycaemia

Abstract

Adding alogliptin to previous insulin therapy (with or without metformin) significantly improved glycaemic control in patients with type 2 diabetes inadequately controlled on insulin, without causing weight gain or increasing the incidence of hypoglycaemia. Further studies are warranted to explore the role of alogliptin added to optimized basal insulin regimens.